LEGNLegend Biotech Corporation
$19.27-40% 1Y
$19.27
$16.6552 weeks$36.28
Is the business good?
How good a business is LEGN?
Legend Biotech Corporation keeps −29% of every revenue dollar as profit after everything, against −86% for the median Biotechnology name.
−29%
Net margin · Biotechnology median −86% · 12 months to Q4 2025
- R&D as % of revenue
- 40%
R&D as % of revenue
- Gross margin
- 61%
Gross margin
| Year | Operating margin |
|---|---|
| FY2020 | 100% |
| FY2021 | 87% |
| FY2022 | 36% |
| FY2023 | −185% |
| FY2024 | −49% |
| FY2025 | −13% |
Details›
- Gross margin12 months to Q4 2025
- 61%
- Net margin12 months to Q4 2025
- −29%
- Free cash flow margin
- −13%
- R&D as % of revenue
- 40%
- Revenue, trailing twelve months
- $1.03B
- Free cash flow, trailing twelve months
- −$129M
- Net income, trailing twelve months
- −$297M
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.
On our screens:Stocks with no debt